#Canada #Mississauga #Kye Pharmaceuticals #DYANAVEL XR

Kye Pharmaceuticals Secures Approval for DYANAVEL® XR

Kye Pharmaceuticals Inc., a prominent specialty pharmaceutical company based in Canada, has recently received the green light from Health Canada for its innovative ADHD treatment, DYANAVEL® XR (amphetamine extended-release). This approval includes both tablet and oral suspension formulations, paving the way for improved management of Attention Deficit Hyperactivity Disorder (ADHD) for patients.

ADHD is a neurodevelopmental condition characterized by symptoms such as inattention, hyperactivity, and impulsivity. Studies show that this disorder affects approximately 3-5% of adults and 5-9% of children and adolescents. Many individuals struggling with ADHD encounter significant challenges in regulating their focus and attention, impacting their daily lives, learning capabilities, and overall behavior.

A Significant Development in ADHD Treatment

DYANAVEL® XR is specifically designated for treating ADHD in adults aged 18 and older and children aged between 6 to 12 years. According to the guidelines established by the Canadian ADHD Resource Alliance (CADDRA), amphetamine-based treatments like DYANAVEL® XR are recommended as first-line medications for ADHD management. By providing a long-acting psychostimulant option, DYANAVEL® XR aims to enhance the quality of life for those living with ADHD.

The technology behind DYANAVEL® XR, known as LiquiXR® extended-release delivery, differentiates it from other treatment options available in Canada. This unique formulation allows for a controlled release of amphetamine over an extended period, resulting in effective symptom control without the peak and trough effects commonly associated with immediate-release therapies. Patients can experience the onset of action one hour after ingestion, with an impressive duration of therapeutic effect lasting up to 13 hours.

Clinical Insights

Dr. Sam Chang, a Child and Adolescent Psychiatrist and Clinical Associate Professor at the University of Calgary, commented on the impact of DYANAVEL® XR, stating, "ADHD is a complex neuro-developmental condition. The goal of treatment is having the patient realize their full potential. Dyanavel® XR will provide an important new option for healthcare professionals to optimize ADHD treatment in adults and children." This sentiment is echoed by Dr. Ghalib Ahmed, an Assistant Clinical Professor at the University of Alberta, who emphasized the necessity of various treatment options that cater to the distinct needs of each person and their families affected by ADHD.

The Future of ADHD Treatment in Canada

John McKendry, President and CEO of Kye Pharmaceuticals, stated, "DYANAVEL® XR, developed using the novel LiquiXR® extended-release delivery technology, is the first and only extended-release oral suspension and chewable tablet form of amphetamine approved in Canada. This approval further solidifies our commitment to providing a diverse portfolio of effective ADHD treatment options."

With the ongoing evolution of ADHD treatment options, Kye Pharmaceuticals is paving the way for innovative solutions that could significantly improve the lives of individuals affected by this condition. The combination of DYANAVEL® XR with existing ADHD medications like Quillivant® ER Oral Suspension and Chewable Tablets equips healthcare professionals with a robust arsenal to address ADHD more effectively.

In conclusion, the approval of DYANAVEL® XR marks a noteworthy milestone for Kye Pharmaceuticals and adds to the existing landscape of ADHD management in Canada. As research and innovation continue to advance, the hope for individuals suffering from ADHD becomes increasingly tangible, bringing brighter prospects for enhanced attention and focus in their everyday lives.